Your browser doesn't support javascript.
New-onset and relapsed liver diseases following COVID-19 vaccination: a systematic review.
Alhumaid, Saad; Al Mutair, Abbas; Rabaan, Ali A; ALShakhs, Fatemah M; Choudhary, Om Prakash; Yong, Shin Jie; Nainu, Firzan; Khan, Amjad; Muhammad, Javed; Alhelal, Fadil; Al Khamees, Mohammed Hussain; Alsouaib, Hussain Ahmed; Al Majhad, Ahmed Salman; Al-Tarfi, Hassan Redha; ALyasin, Ali Hussain; Alatiyyah, Yaqoub Yousef; Alsultan, Ali Ahmed; Alessa, Mohammed Essa; Alessa, Mustafa Essa; Alissa, Mohammed Ahmed; Alsayegh, Emad Hassan; Alshakhs, Hassan N; Al Samaeel, Haidar Abdullah; AlShayeb, Rugayah Ahmed; Alnami, Dalal Ahmed; Alhassan, Hussain Ali; Alabdullah, Abdulaziz Abdullah; Alhmed, Ayat Hussain; AlDera, Faisal Hussain; Hajissa, Khalid; Al-Tawfiq, Jaffar A; Al-Omari, Awad.
  • Alhumaid S; Administration of Pharmaceutical Care, Al-Ahsa Health Cluster, Ministry of Health, Rashdiah Street, P. O. Box 12944, Al-Ahsa, 31982, Saudi Arabia. saalhumaid@moh.gov.sa.
  • Al Mutair A; Research Center, Almoosa Specialist Hospital, Al-Ahsa, Saudi Arabia.
  • Rabaan AA; College of Nursing, Princess Norah Bint Abdul Rahman University, Riyadh, Saudi Arabia.
  • ALShakhs FM; School of Nursing, University of Wollongong, Wollongong, Australia.
  • Choudhary OP; Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia.
  • Yong SJ; College of Medicine, Alfaisal University, Riyadh, 11533, Saudi Arabia.
  • Nainu F; Department of Public Health and Nutrition, The University of Haripur, Haripur, Pakistan.
  • Khan A; Respiratory Therapy Department, Prince Saud Bin Jalawi Hospital, Ministry of Health, Al-Ahsa, Saudi Arabia.
  • Muhammad J; Department of Veterinary Anatomy and Histology, College of Veterinary Sciences and Animal Husbandry, Central Agricultural University (I), Selesih, Aizawl, Mizoram, 796015, India.
  • Alhelal F; Department of Biological Sciences, School of Medical and Life Sciences, Sunway University, Subang Jaya, Malaysia.
  • Al Khamees MH; Department of Pharmacy, Faculty of Pharmacy, Hasanuddin University, Makassar, 90245, Indonesia.
  • Alsouaib HA; Department of Public Health and Nutrition, The University of Haripur, Haripur, Pakistan.
  • Al Majhad AS; Department of Microbiology, The University of Haripur, Haripur, 22620, Khyber Pakhtunkhwa, Pakistan.
  • Al-Tarfi HR; Optometry Department, Dhahran Eye Specialist Hospital, Ministry of Health, Dhahran, Saudi Arabia.
  • ALyasin AH; Molecular Pathology Laboratory, King Fahad Hofuf Hospital, Ministry of Health, Al-Ahsa, Saudi Arabia.
  • Alatiyyah YY; Medical Store Department, Maternity and Children Hospital, Ministry of Health, Al-Ahsa, Saudi Arabia.
  • Alsultan AA; Medical Store Department, Maternity and Children Hospital, Ministry of Health, Al-Ahsa, Saudi Arabia.
  • Alessa ME; Medical Store Department, Maternity and Children Hospital, Ministry of Health, Al-Ahsa, Saudi Arabia.
  • Alessa ME; Medical Store Department, Maternity and Children Hospital, Ministry of Health, Al-Ahsa, Saudi Arabia.
  • Alissa MA; Department of Pharmacy, Hereditary Blood Diseases Centre, Al-Ahsa, Saudi Arabia.
  • Alsayegh EH; Medical Supply Store, Aloyoon General Hospital, Ministry of Health, Al-Ahsa, Saudi Arabia.
  • Alshakhs HN; Inventory Control Unit, Aloyoon General Hospital, Ministry of Health, Al-Ahsa, Saudi Arabia.
  • Al Samaeel HA; Pharmacy Department, Aloyoon General Hospital, Ministry of Health, Al-Ahsa, Saudi Arabia.
  • AlShayeb RA; Pharmacy Department, Aloyoon General Hospital, Ministry of Health, Al-Ahsa, Saudi Arabia.
  • Alnami DA; Pharmacy Department, Aloyoon General Hospital, Ministry of Health, Al-Ahsa, Saudi Arabia.
  • Alhassan HA; Pharmacy Department, Aloyoon General Hospital, Ministry of Health, Al-Ahsa, Saudi Arabia.
  • Alabdullah AA; Pharmacy Department, Prince Saud Bin Jalawi Hospital, Ministry of Health, Al-Ahsa, Saudi Arabia.
  • Alhmed AH; Pharmacy Department, King Fahad Hofuf Hospital, Ministry of Health, Al-Ahsa, Saudi Arabia.
  • AlDera FH; Pharmacy Department, King Fahad Hofuf Hospital, Ministry of Health, Al-Ahsa, Saudi Arabia.
  • Hajissa K; Pharmacy Department, Maternity and Children Hospital, Ministry of Health, Al-Ahsa, Saudi Arabia.
  • Al-Tawfiq JA; Pharmacy Department, Maternity and Children Hospital, Ministry of Health, Al-Ahsa, Saudi Arabia.
  • Al-Omari A; Administration of Nursing Care, Maternity and Children Hospital, Ministry of Health, Al-Ahsa, Saudi Arabia.
BMC Gastroenterol ; 22(1): 433, 2022 Oct 13.
Статья в английский | MEDLINE | ID: covidwho-2064737
ABSTRACT

BACKGROUND:

Liver diseases post-COVID-19 vaccination is extremely rare but can occur. A growing body of evidence has indicated that portal vein thrombosis, autoimmune hepatitis, raised liver enzymes and liver injuries, etc., may be potential consequence of COVID-19 vaccines.

OBJECTIVES:

To describe the results of a systematic review for new-onset and relapsed liver disease following COVID-19 vaccination.

METHODS:

For this systematic review, we searched Proquest, Medline, Embase, PubMed, CINAHL, Wiley online library, Scopus and Nature through the Preferred Reporting Items for Systematic Reviews and Meta Analyses PRISMA guideline for studies on the incidence of new onset or relapsed liver diseases post-COVID-19 vaccination, published from December 1, 2020 to July 31, 2022, with English language restriction.

RESULTS:

Two hundred seventy-five cases from one hundred and eighteen articles were included in the qualitative synthesis of this systematic review. Autoimmune hepatitis (138 cases) was the most frequent pathology observed post-COVID-19 vaccination, followed by portal vein thrombosis (52 cases), raised liver enzymes (26 cases) and liver injury (21 cases). Other cases include splanchnic vein thrombosis, acute cellular rejection of the liver, jaundice, hepatomegaly, acute hepatic failure and hepatic porphyria. Mortality was reported in any of the included cases for acute hepatic failure (n = 4, 50%), portal vein thrombosis (n = 25, 48.1%), splanchnic vein thrombosis (n = 6, 42.8%), jaundice (n = 1, 12.5%), raised liver enzymes (n = 2, 7.7%), and autoimmune hepatitis (n = 3, 2.2%). Most patients were easily treated without any serious complications, recovered and did not require long-term hepatic therapy.

CONCLUSION:

Reported evidence of liver diseases post-COIVD-19 vaccination should not discourage vaccination against this worldwide pandemic. The number of reported cases is relatively very small in relation to the hundreds of millions of vaccinations that have occurred and the protective benefits offered by COVID-19 vaccination far outweigh the risks.
Тема - темы
ключевые слова

Полный текст: Имеется в наличии Коллекция: Международные базы данных база данных: MEDLINE Основная тема: Liver Failure, Acute / Hepatitis, Autoimmune / Venous Thrombosis / COVID-19 Vaccines / COVID-19 Тип исследования: Наблюдательное исследование / Прогностическое исследование / Качественное исследование / Отзывы / Систематический обзор/метаанализ Темы: Длинный Ковид / Вакцина Пределы темы: Люди Язык: английский Журнал: BMC Gastroenterol Тематика журнала: Гастроэнтерология Год: 2022 Тип: Статья Аффилированная страна: S12876-022-02507-3

Документы, близкие по теме

MEDLINE

...
LILACS

LIS


Полный текст: Имеется в наличии Коллекция: Международные базы данных база данных: MEDLINE Основная тема: Liver Failure, Acute / Hepatitis, Autoimmune / Venous Thrombosis / COVID-19 Vaccines / COVID-19 Тип исследования: Наблюдательное исследование / Прогностическое исследование / Качественное исследование / Отзывы / Систематический обзор/метаанализ Темы: Длинный Ковид / Вакцина Пределы темы: Люди Язык: английский Журнал: BMC Gastroenterol Тематика журнала: Гастроэнтерология Год: 2022 Тип: Статья Аффилированная страна: S12876-022-02507-3